{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Demyelinating+Autoimmune+Diseases%2C+Central+Nervous+System+%28CNS%29&page=6",
    "query": {
      "condition": "Demyelinating Autoimmune Diseases, Central Nervous System (CNS)",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 262,
    "total_pages": 27,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Demyelinating+Autoimmune+Diseases%2C+Central+Nervous+System+%28CNS%29&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Demyelinating+Autoimmune+Diseases%2C+Central+Nervous+System+%28CNS%29&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T11:52:09.560Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03887273",
      "title": "Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Transverse Myelitis"
      ],
      "interventions": [
        {
          "name": "Q-Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Q Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 9,
      "start_date": "2022-09-20",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-10-23T11:52:09.560Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03887273"
    },
    {
      "nct_id": "NCT01874145",
      "title": "Safety and Tolerability of Glatiramer Acetate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing-Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "GA 20 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "GA 40 mg/mL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 209,
      "start_date": "2013-06",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2016-01-14",
      "last_synced_at": "2026-10-23T11:52:09.560Z",
      "location_count": 35,
      "location_summary": "Cullman, Alabama • Gilbert, Arizona • Phoenix, Arizona + 31 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01874145"
    },
    {
      "nct_id": "NCT00704626",
      "title": "Serum Auto-Antibodies in Neurological Diseases",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis",
        "Myasthenia Gravis",
        "Transverse Myelitis"
      ],
      "interventions": [
        {
          "name": "Blood Draw",
          "type": "OTHER"
        },
        {
          "name": "Cheek swab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2002-01",
      "completion_date": "2031-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-10-23T11:52:09.560Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00704626"
    },
    {
      "nct_id": "NCT00097188",
      "title": "A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 104,
      "start_date": "2004-12",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2014-03-04",
      "last_synced_at": "2026-10-23T11:52:09.560Z",
      "location_count": 31,
      "location_summary": "Phoenix, Arizona • Loma Linda, California • Modesto, California + 28 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00097188"
    },
    {
      "nct_id": "NCT00071838",
      "title": "Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Daclizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2003-10-30",
      "completion_date": "2011-08-16",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-23T11:52:09.560Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00071838"
    },
    {
      "nct_id": "NCT00716066",
      "title": "Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autoimmune Disease",
        "Neurologic Autoimmune Disease",
        "Autologous Transplant Autoimmune",
        "Multiple Sclerosis Transplant",
        "MS Stem Cell Transplant",
        "Multiple Sclerosis Stem Cell Transplant",
        "Stiff Person Syndrome",
        "HCT for Neurologic Autoimmune Disorders",
        "CIDP Transplant",
        "Myasthenia Gravis Transplant",
        "Autoimmune Nervous System Disorder",
        "Central Nervous System Vasculitis",
        "Cerebellar Degeneration",
        "Chronic Inflammatory Demyelinating Polyneuropathy",
        "Lambert Eaton Myasthenic Syndrome",
        "Myasthenia Gravis",
        "Neuromyelitis Optica",
        "Opsoclonus Myoclonus Syndrome",
        "Rasmussen Subacute Encephalitis"
      ],
      "interventions": [
        {
          "name": "Anti-Thymocyte Globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Syngeneic Bone Marrow Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "71 Years",
        "sex": "ALL",
        "summary": "Up to 71 Years"
      },
      "enrollment_count": 53,
      "start_date": "2008-06",
      "completion_date": "2030-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-10-23T11:52:09.560Z",
      "location_count": 3,
      "location_summary": "Denver, Colorado • Seattle, Washington",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00716066"
    },
    {
      "nct_id": "NCT04837651",
      "title": "Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis",
        "Demyelinating Autoimmune Diseases, CNS",
        "Autoimmune Diseases of the Nervous System",
        "Nervous System Diseases",
        "Demyelinating Diseases",
        "Autoimmune Diseases",
        "Immune System Diseases",
        "Pathologic Processes"
      ],
      "interventions": [
        {
          "name": "Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test",
          "type": "DEVICE"
        },
        {
          "name": "T-Detect COVID T-cell blood test",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Dragonfly Research, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2021-03-02",
      "completion_date": "2021-07-01",
      "has_results": false,
      "last_update_posted_date": "2021-08-02",
      "last_synced_at": "2026-10-23T11:52:09.560Z",
      "location_count": 1,
      "location_summary": "Wellesley, Massachusetts",
      "locations": [
        {
          "city": "Wellesley",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04837651"
    },
    {
      "nct_id": "NCT05732285",
      "title": "A Pilot Randomized Controlled Trial: CoINTEGRATE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neurocognitive Disorders",
        "Cognitive Dysfunction",
        "Traumatic Brain Injury",
        "Multiple Sclerosis",
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "CRT",
          "type": "BEHAVIORAL"
        },
        {
          "name": "CBT",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Modifiable lifestyle factors",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Usual care Psychoeducation",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 15,
      "start_date": "2023-09-01",
      "completion_date": "2025-10-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-10-23T11:52:09.560Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05732285"
    },
    {
      "nct_id": "NCT03710278",
      "title": "The Effectiveness and Safety of Human Lumbar Puncture Assist Device (LPat)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Meningitis",
        "Encephalitis",
        "Guillain-Barré",
        "Subarachnoid Hemorrhage",
        "Intracranial Neoplasm",
        "Intracranial CNS Disorder"
      ],
      "interventions": [
        {
          "name": "LPat Device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Spartanburg Regional Healthcare System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2017-12-21",
      "completion_date": "2019-01-23",
      "has_results": false,
      "last_update_posted_date": "2019-09-18",
      "last_synced_at": "2026-10-23T11:52:09.560Z",
      "location_count": 1,
      "location_summary": "Spartanburg, South Carolina",
      "locations": [
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03710278"
    },
    {
      "nct_id": "NCT00424788",
      "title": "A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Relapsing Forms of Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Plasma exchange",
          "type": "PROCEDURE"
        },
        {
          "name": "natalizumab treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 12,
      "start_date": "2007-01",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2009-09-04",
      "last_synced_at": "2026-10-23T11:52:09.560Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00424788"
    }
  ]
}